Dr. Huijun Zhou 周慧俊
Chief Physician
Department of Medical Oncology, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, targeted therapy, immunotherapy, and comprehensive treatment for digestive tumors, including esophageal, gastric, colorectal, and hepatobiliary-pancreatic malignancies.
Dr. Zhou is Deputy Director of the Department of Digestive and Urinary Internal Medicine I at Hunan Cancer Hospital and holds a doctorate in oncology. Recognized as a Young Backbone Talent (2023) and Discipline Leader (2024) in Hunan Province, Dr. Zhou serves as a postdoctoral cooperative supervisor.
Professional roles
- Standing Committee Member, Hunan Branch of Chinese Medical Association
- Vice Chair, Tumor Targeted Therapy Professional Committee, Hunan Anti-Cancer Association
- Vice Chair, Esophageal Cancer Branch, Hunan Geriatrics Society
- Member, Esophageal Tumor Integrated Rehabilitation Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhou Huijun). Papers usually list the name as Huijun Zhou or Zhou H.
Selected publications
33 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Mol Med, 2025 (first author): MTHFD2 promotes esophageal squamous cell carcinoma progression via m6A modification‑mediated upregulation and modulation of the PEBP1‑RAF1 interaction. PubMed 40052596
- J Gastrointest Oncol, 2023 (senior author): Efficacy, safety, and predictors of fruquintinib plus anti-programmed death receptor-1 (PD-1) antibody in refractory microsatellite stable metastatic colorectal cancer in a real-world setting: a retrospective cohort study. PubMed 38196544
- Clin Transl Oncol, 2023 (senior author): Effect of tumor exosome-derived Lnc RNA HOTAIR on the growth and metastasis of gastric cancer. PubMed 37199906
- Front Med (Lausanne), 2023 (senior author): Surgical resection for second primary colorectal cancer: a population-based study. PubMed 37425303
- Am J Transl Res, 2023 (first author): Correlation analysis of the expression of mesenchymal circulating tumor cells and CD133 with the prognosis of colorectal cancer. PubMed 37303671
- Cancers (Basel), 2023 (first author): F-Box Protein 43, Stabilized by N6-Methyladenosine Methylation, Enhances Hepatocellular Carcinoma Cell Growth and Invasion via Promoting p53 Degradation in a Ubiquitin Conjugating Enzyme E2 C-Dependent Manner. PubMed 36765911
- Comput Methods Programs Biomed, 2023 (first author): Classification of precancerous lesions based on fusion of multiple hierarchical features. PubMed 36516661
- J Biomed Nanotechnol, 2022 (first author): Study on the Expression of β-1,3-N-acetylglucosaminyltransferase 3 in Gastric Cancer and the Mechanism Promoting Gastric Cancer Progression Based on the Extraction Method of Nanomagnetic Beads. PubMed 35715910
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion